8-K: Semper Paratus Acquisition Corporation Announces Nasdaq Listing for Tevogen Bio Following Business Combination

Semper Paratus Acquisition Corporation has filed a supplement to its proxy statement, announcing the planned listing of Tevogen Bio Holdings Inc. on the Nasdaq Stock Market instead of the NYSE American.

Summary

• Semper Paratus Acquisition Corporation has announced a change in listing plans for Tevogen Bio following their business combination.
• The combined entity, Tevogen Bio Holdings Inc., will now seek to list its common stock and public warrants on the Nasdaq Stock Market.
• This change is detailed in a supplement to the definitive proxy statement/prospectus filed on January 24, 2024.
• The extraordinary general meeting of Semper Paratus shareholders to vote on the business combination is scheduled for January 29, 2024.
• The business combination involves Semper Paratus redomiciling from the Cayman Islands to Delaware and merging with Tevogen Bio.
• Tevogen Bio will become a wholly-owned subsidiary of the newly formed Tevogen Bio Holdings Inc.

Sentiment

Score: 6

Explanation: The document is generally neutral, outlining a change in listing venue and reiterating the terms of the business combination. While it highlights positive aspects of Tevogen Bio, it also includes significant risk factors, resulting in a moderate sentiment score.

Positives

• The move to Nasdaq may provide greater visibility and access to a broader investor base.
• Tevogen Bio is a clinical-stage immunotherapy company with a focus on innovative T-cell therapies.
• Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial.
• Tevogen Bio owns its key intellectual property assets, including three granted patents and twelve pending patents.

Negatives

• The document highlights risks associated with the business combination, including potential failure to complete the merger.
• There are risks related to shareholder redemptions and the ability to meet Nasdaq listing standards.
• The document mentions the risk of not realizing the anticipated benefits of the business combination.

Risks

• The business combination may not be completed by Semper Paratus' deadline.
• Failure to satisfy closing conditions, including shareholder approval and minimum cash requirements, could prevent the merger.
• Shareholder redemptions could exceed anticipated levels, impacting the available cash.
• The combined company may not meet Nasdaq initial listing standards.
• The business combination could disrupt Tevogen Bio's current operations.
• Legal proceedings related to the merger could arise.
• Tevogen Bio may face challenges in executing its growth strategies.
• The company may need to raise additional capital, which may not be available on acceptable terms.
• There are risks associated with product liability and regulatory lawsuits.
• Uncertainties exist in the execution of preclinical studies and clinical trials.
• The company has a limited operating history.

Future Outlook

The document outlines the intention to complete the business combination and list the new entity on the Nasdaq, but it also includes numerous risk factors that could impact the success of the merger and the future performance of the combined company.

Management Comments

• Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models.
• Tevogen Bios leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Industry Context

This announcement reflects a trend of biotech companies seeking public listings through SPAC mergers, and the change in listing venue from NYSE American to Nasdaq suggests a strategic decision to target a different investor base or achieve better valuation.

Comparison to Industry Standards

• Many biotech companies, such as Ginkgo Bioworks and 23andMe, have gone public via SPAC mergers, indicating a common path for companies in this sector.
• The decision to list on Nasdaq instead of NYSE American is a strategic choice, with Nasdaq often being favored by technology and growth-oriented companies, such as Moderna and BioNTech.
• Tevogen Bio's focus on T-cell therapies aligns with a growing area of interest in the biotech industry, with companies like Kite Pharma and Juno Therapeutics leading the way in CAR T-cell therapies.

Stakeholder Impact

• Shareholders of Semper Paratus will vote on the proposed merger and will receive shares in the new entity.
• Employees of Tevogen Bio will become part of the new combined entity.
• Customers and partners of Tevogen Bio will be impacted by the merger and the future direction of the company.
• The listing on Nasdaq may provide greater liquidity for investors.

Next Steps

• Semper Paratus shareholders will vote on the business combination on January 29, 2024.
• The business combination is expected to close if all conditions are met.
• Tevogen Bio Holdings Inc. will seek to list on the Nasdaq Stock Market.

Key Dates

Keywords

Business Combination, Tevogen Bio, Semper Paratus, Nasdaq, Merger, Listing, Immunotherapy, SPAC, Redomiciliation, Warrants